Table 2.
Objective responses and timing of responses to avelumab.
| All patients | BMI<30 | BMI≥ 30 | |
|---|---|---|---|
| No. of Patients (%) | 32 (100) | 20 (62.5) | 12 (37.5) |
|
Time to
Response, Median (range), months |
4 (2-7) | 3.5 (2-7) | 6 (3-7) |
|
Overall Response
(CR + PR), No. (%) |
17 (53.1) | 12 (60.0) | 5 (41.7) |
|
Best Response, No. (%)
CR PR SD PD |
3 (9.4) 14 (43.8) 8 (25.0) 7 (21.8) |
2 (10.0) 10 (50.0) 3 (15.0) 5 (25.0) |
1 (8.3) 4 (33.3) 5 (41.7) 2 (16.7) |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.